Cargando…
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased th...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576324/ https://www.ncbi.nlm.nih.gov/pubmed/33296987 http://dx.doi.org/10.1016/j.msard.2020.102592 |